A total of 60 patients diagnosed with CML and treated with TKIs were prospectively monitored through the quantitative evaluation of the BCR::ABL1 transcript level (by RT-qPCR) at 3 months following initiation of TKI, between May 2018 and June 2023. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.